Data shared at TIDES Europe demonstrates consistent and robust platform performance while delivering high product quality at scale, alongside new platform capabilities in targeting functionality and initial results showcasing that stereochemical control relates to biological efficacy
REDWOOD CITY, Calif., Nov. 09, 2026 (GLOBE NEWSWIRE) -- Codexis, Inc. (NASDAQ: CDXS) a leading provider of enzymatic solutions for efficient and scalable manufacturing of complex oligonucleotide therapeutics, presented new data at TIDES Europe 2026 demonstrating the quality, stereo-control and manufacturing performance of its ECO Synthesis® Manufacturing Platform. The data included product quality and manufacturing control at 100-gram scale, improved process performance and initial biological evidence supporting the potential value of defined siRNA stereochemistry.
Codexis presented data demonstrating significant gains in manufacturing efficiency at the 100-gram scale, achieving product quality above 90% while nearly halving cycle time. Importantly, this performance was maintained consistently across three orders of magnitude in scale.
"As enzymatic RNA manufacturing advances, the important question is...